ICER

QALYs Under Fire

December 3, 2019

The QALY gives a one-size-fits-all measure of value that doesn’t reflect the needs and experiences of real patients.

ICER Videos

November 12, 2019

If you don’t know ICER, you should.  IfPA’s new videos explain what the health economic organization is leaving out of…

ICER and the Real World

September 10, 2019

ICER recently released an updated draft of its framework. What do these changes mean for real patients who want to access innovative medicine?

Breakthrough Cystic Fibrosis Treatment on the Horizon

June 7, 2019

Elated. Nervous. Hopeful. That’s how thousands of cystic fibrosis patients felt upon hearing last week’s news: the Food and Drug Administration will soon review a new triple combination therapy that could drastically improve their quality of life.

How ICER Gets it Wrong

August 9, 2018

An influential calculation of how new drugs impact annual spending is flawed – and patients may be paying the price in reduced access to innovative medicine.

Final ICER Report Leaves Cystic Fibrosis Community Uneasy

June 8, 2018

Economists at the Institute for Clinical and Economic Review advise a whopping 77 percent price discount on new CFTR modulators for cystic fibrosis, according to a final evidence report.  The drugs can “substantially improve patient health outcomes,” the group concedes, but their prices exceed ICER’s cost-effectiveness threshold. One manufacturer has called ICER’s analysis “a sham.”